CR10912A - Preparacion framaceutica para reducir la endometriosis - Google Patents
Preparacion framaceutica para reducir la endometriosisInfo
- Publication number
- CR10912A CR10912A CR10912A CR10912A CR10912A CR 10912 A CR10912 A CR 10912A CR 10912 A CR10912 A CR 10912A CR 10912 A CR10912 A CR 10912A CR 10912 A CR10912 A CR 10912A
- Authority
- CR
- Costa Rica
- Prior art keywords
- framaceutical
- preparation
- endometriosis
- reduce
- reduce endometriosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composicion farmaceutica para el tratamiento de endometrisis sin reducir la densidad osea contiene un gestageno con eficacia antiandrogenica, con preferencia 17a-cianometil-17B-hidroxiestra-4,9-dien-3-ona (dienogest), acetato de ciproterona o acetato de cloromadinona en una dosis diaria que es como maximo el doble de la dosis inhibidora de la ovulacion, junto con uno o varios excipientes/portadores farmaceuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07004202A EP1977752A1 (de) | 2007-03-01 | 2007-03-01 | Pharmazeutische Zubereitung zur Verminderung der Endometriose |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10912A true CR10912A (es) | 2009-08-13 |
Family
ID=38045772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10912A CR10912A (es) | 2007-03-01 | 2009-07-03 | Preparacion framaceutica para reducir la endometriosis |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP1977752A1 (es) |
JP (1) | JP2010520159A (es) |
KR (1) | KR20090119829A (es) |
CN (1) | CN101583364A (es) |
AU (1) | AU2008221012A1 (es) |
BR (1) | BRPI0806598A2 (es) |
CA (1) | CA2673936A1 (es) |
CO (1) | CO6190606A2 (es) |
CR (1) | CR10912A (es) |
DO (1) | DOP2009000171A (es) |
EA (1) | EA200900829A1 (es) |
EC (1) | ECSP099482A (es) |
MA (1) | MA31162B1 (es) |
MX (1) | MX2009007259A (es) |
NZ (1) | NZ577761A (es) |
SV (1) | SV2009003324A (es) |
TN (1) | TN2009000263A1 (es) |
WO (1) | WO2008104342A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101874806A (zh) * | 2009-04-29 | 2010-11-03 | 北京本草天源药物研究院 | 一种地诺孕素固体制剂 |
CN102670519B (zh) * | 2011-03-16 | 2014-06-11 | 重庆莱美药业股份有限公司 | 一种可快速溶出的地诺孕素口服制剂及其制备方法 |
CN103304619B (zh) * | 2013-06-08 | 2015-12-02 | 西藏海思科药业集团股份有限公司 | 一种地诺孕素化合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4426601A1 (de) * | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
EP1535618A1 (en) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
DE102004026679A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
EP1655031A1 (de) * | 2004-10-08 | 2006-05-10 | Schering AG | Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung |
-
2007
- 2007-03-01 EP EP07004202A patent/EP1977752A1/de not_active Withdrawn
-
2008
- 2008-02-23 KR KR1020097014169A patent/KR20090119829A/ko not_active Application Discontinuation
- 2008-02-23 WO PCT/EP2008/001451 patent/WO2008104342A1/de active Application Filing
- 2008-02-23 EP EP08707797A patent/EP2059248A1/de not_active Ceased
- 2008-02-23 NZ NZ577761A patent/NZ577761A/en not_active IP Right Cessation
- 2008-02-23 CN CNA2008800023330A patent/CN101583364A/zh active Pending
- 2008-02-23 AU AU2008221012A patent/AU2008221012A1/en not_active Abandoned
- 2008-02-23 BR BRPI0806598-5A patent/BRPI0806598A2/pt not_active IP Right Cessation
- 2008-02-23 CA CA002673936A patent/CA2673936A1/en not_active Abandoned
- 2008-02-23 EA EA200900829A patent/EA200900829A1/ru unknown
- 2008-02-23 MX MX2009007259A patent/MX2009007259A/es unknown
- 2008-02-23 JP JP2009551120A patent/JP2010520159A/ja active Pending
-
2009
- 2009-06-24 TN TNP2009000263A patent/TN2009000263A1/fr unknown
- 2009-07-03 SV SV2009003324A patent/SV2009003324A/es not_active Application Discontinuation
- 2009-07-03 CR CR10912A patent/CR10912A/es unknown
- 2009-07-03 EC EC2009009482A patent/ECSP099482A/es unknown
- 2009-07-03 CO CO09068629A patent/CO6190606A2/es not_active Application Discontinuation
- 2009-07-03 DO DO2009000171A patent/DOP2009000171A/es unknown
- 2009-08-04 MA MA32138A patent/MA31162B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2008104342A1 (de) | 2008-09-04 |
ECSP099482A (es) | 2009-08-28 |
DOP2009000171A (es) | 2009-08-31 |
AU2008221012A1 (en) | 2008-09-04 |
EP2059248A1 (de) | 2009-05-20 |
KR20090119829A (ko) | 2009-11-20 |
BRPI0806598A2 (pt) | 2014-05-06 |
MX2009007259A (es) | 2009-07-10 |
SV2009003324A (es) | 2009-10-02 |
MA31162B1 (fr) | 2010-02-01 |
JP2010520159A (ja) | 2010-06-10 |
EA200900829A1 (ru) | 2010-02-26 |
NZ577761A (en) | 2012-03-30 |
TN2009000263A1 (en) | 2010-10-18 |
CO6190606A2 (es) | 2010-08-19 |
CA2673936A1 (en) | 2008-09-04 |
EP1977752A1 (de) | 2008-10-08 |
CN101583364A (zh) | 2009-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20091954L (no) | Anvendelse av ostradiolvalerat eller 17ß-ostradil i kombinasjon med dienogest for oral terapi for opprettholdelse og/eller okning av kvinnelig libido | |
CL2011003266A1 (es) | Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras. | |
UY33343A (es) | Formas de dosificación sólidas orales con dosis muy bajas para la hrt | |
JP2016053040A5 (es) | ||
NZ594022A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof | |
MY160768A (en) | Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease | |
UY32260A (es) | Forma de dosificación farmacéutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o diuretico | |
UA106634C2 (uk) | Тверда фармацевтична дозована форма | |
AR061959A1 (es) | Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas | |
TN2011000651A1 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application | |
CR10912A (es) | Preparacion framaceutica para reducir la endometriosis | |
AR053546A1 (es) | Forma farmacologica peroral solida para la anticoncepcion | |
MX2010004513A (es) | Proceso de obtencion de un extracto estandarizado, extracto obtenido, composicion farmaceutica, metodo de tratamiento y uso de dicho extracto. | |
CL2015003014A1 (es) | Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas. | |
AR080541A1 (es) | Tratamiento para la endometriosis | |
MX2010005009A (es) | Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales. | |
CR9324A (es) | Preparación farmacéutica para la anticoncepción oral | |
AR116592A1 (es) | Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib | |
CU20090116A7 (es) | Preparación farmacéutica para reducir la endometriosis | |
PA8793901A1 (es) | Uso de gestágenos en combinación con (6s)-5-metiltetrahidrofolato para la terapia la endometriosis con simultánea reducción de los efectos colaterales terapéuticos, así como reducción del riesgo de malformaciones congénitas al comenzar un embarazo | |
CU20110070A6 (es) | Método para tratar la endometriosis sin disminuir la densidad ósea | |
UY30530A1 (es) | Forma farmacologica peroral para la anticoncepcion | |
SI2285367T1 (sl) | Farmacevtski sestavek za zdravljenje bradavic | |
PE20091020A1 (es) | Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa | |
PE20090479A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivante y un agente benzodiazepinico, indicada para el control y tratamiento de trastornos convulsivos y sindromes epilepticos |